Skip to main content
SPT logo

SPT — Investor Relations & Filings

Ticker · 1789 ISIN · TW0001789006 TW Manufacturing
Open in API
Filings indexed 2,231 across all filing types
Latest filing 2024-06-13 Regulatory Filings
Country TW Taiwan
Listing TW 1789

About SPT

https://www.scinopharm.com/tw

ScinoPharm Taiwan, Ltd. is a global provider of high-quality Active Pharmaceutical Ingredients (APIs) and comprehensive Contract Development and Manufacturing Organization (CDMO) services. The company specializes in process research, development, and cGMP production, maintaining a leadership position in oncology APIs. Its portfolio covers therapeutic areas including cancer, hematology, metabolic disorders, and central nervous system diseases. ScinoPharm offers one-stop solutions encompassing peptide synthesis, API process development, and the manufacturing of sterile injectables and complex generics. The company is distinguished by its expertise in high-barrier pharmaceutical technologies and adherence to stringent international regulatory standards, such as the U.S. FDA. Serving both generic and innovative drug sectors, it leverages advanced R&D and integrated manufacturing to support global healthcare markets.

Recent filings

Filing Released Lang Actions
113年年報及股東會資料 — 2023_1789_20240528F04.pdf
Regulatory Filings
2024-06-13 Chinese
113年年報及股東會資料 — 2024_1789_20240528F17.pdf
Major Shareholding Notification Classification · 95% confidence The document contains detailed tables listing the top ten shareholders and their shareholding relationships as of specific dates, including information about shareholding percentages, relationships among shareholders, and representatives. The content focuses on ownership structure and related party relationships among major shareholders. This type of information is characteristic of a Major Shareholding Notification, which reports changes or details about significant share ownership levels and relationships among major shareholders. There is no indication of financial statements, management discussion, voting results, or other report types. The document length is over 6000 characters, indicating it is a substantive report rather than a brief announcement. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2024-06-13 Chinese
113年年報及股東會資料 — 2024_1789_20240528FE2.pdf
Regulatory Filings
2024-06-13 Chinese
113年年報及股東會資料 — 2024_1789_20240528FE1.pdf
AGM Information Classification · 95% confidence The document is a notice for the 2024 Annual General Shareholders' Meeting of ScinoPharm Taiwan, Ltd. It includes the meeting agenda, date, location, and procedural details such as voting and proxy information. It also mentions the proposed cash dividend and the closing of share transfer registration. The document is relatively short (3073 characters) and serves as an announcement to shareholders about the upcoming AGM and related matters. It does not contain the full annual report, financial statements, or detailed financial data. Therefore, it fits the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or notices about the AGM itself.
2024-06-13 Chinese
113年年報及股東會資料 — 2024_1789_20240528F13.pdf
Regulatory Filings
2024-06-13 Chinese
113年年報及股東會資料 — 2024_1789_20240528F02.pdf
Regulatory Filings
2024-06-13 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.